An Integrated Computational Pipeline to Construct Patient-Specific Cancer Models

Precision oncology largely involves tumor genomics to guide therapy protocols. Yet, it is well known that many commonly mutated genes cannot be easily targeted. Even when genes can be targeted, resistance to therapy is quite common. A rising field with promising results is that of mathematical biology, where in silico models are often used for the discovery of general principles and novel hypotheses that can guide the development of new treatments. A major goal is that eventually in silico models will accurately predict clinically relevant endpoints and find optimal control interventions to stop (or reverse) disease progression. Thus, it is vital to develop an ecosystem of researchers to optimize the model creation and analysis pipeline. The modeling pipeline posited within this dissertation (dubbed the Synergistic Model Acquisition and Target Analysis (SMATA) pipeline) includes equation learning (to develop topological network communications and functions), attractor analysis, application of phenotype control theory, and simulation of suggested targets. The results herein help provide a proof of concept in the path towards personalized medicine through a means of mathematical systems biology. As such, we apply these strategies to one of the most detrimental cancers, Pancreatic Ductal Adenocarcinoma (PDAC). While any cancer diagnosis is life-altering, pancreatic cancer is among the most discouraging to receive because of its extreme difficulty to overcome. Using our pipeline, we were able to corroborate previous publications and even make some new promising discoveries

Novel miniaturised and highly versatile biomechatronic platforms for the characterisation of melanoma cancer cells

There has been an increasing demand to acquire highly sensitive devices that are able to detect and characterize cancer at a single cell level. Despite the moderate progress in this field, the majority of approaches failed to reach cell characterization with optimal sensitivity and specificity. Accordingly, in this study highly sensitive, miniaturized-biomechatronic platforms have been modeled, designed, optimized, microfabricated, and characterized, which can be used to detect and differentiate various stages of melanoma cancer cells. The melanoma cell has been chosen as a legitimate cancer model, where electrophysiological and analytical expression of cell-membrane potential have been derived, and cellular contractile force has been obtained through a correlation with micromechanical deflections of a miniaturized cantilever beam. The main objectives of this study are in fourfold: (1) to quantify cell-membrane potential, (2) correlate cellular biophysics to respective contractile force of a cell in association with various stages of the melanoma disease, (3) examine the morphology of each stage of melanoma, and (4) arrive at a relation that would interrelate stage of the disease, cellular contractile force, and cellular electrophysiology based on conducted in vitro experimental findings. Various well-characterized melanoma cancer cell lines, with varying degrees of genetic complexities have been utilized. In this study, two-miniaturized-versatile-biomechatronic platforms have been developed to extract the electrophysiology of cells, and cellular mechanics (mechanobiology). The former platform consists of a microfluidic module, and stimulating and recording array of electrodes patterned on a glass substrate, forming multi-electrode arrays (MEAs), whereas the latter system consists of a microcantilever-based biosensor with an embedded Wheatstone bridge, and a microfluidic module. Furthermore, in support of this work main objectives, dedicated microelectronics together with customized software have been attained to functionalize, and empower the two-biomechatronic platforms. The bio-mechatronic system performance has been tested throughout a sufficient number of in vitro experiments.Open Acces

Micro/nanofluidic and lab-on-a-chip devices for biomedical applications

Micro/Nanofluidic and lab-on-a-chip devices have been increasingly used in biomedical research [1]. Because of their adaptability, feasibility, and cost-efficiency, these devices can revolutionize the future of preclinical technologies. Furthermore, they allow insights into the performance and toxic effects of responsive drug delivery nanocarriers to be obtained, which consequently allow the shortcomings of two/three-dimensional static cultures and animal testing to be overcome and help to reduce drug development costs and time [2–4]. With the constant advancements in biomedical technology, the development of enhanced microfluidic devices has accelerated, and numerous models have been reported. Given the multidisciplinary of this Special Issue (SI), papers on different subjects were published making a total of 14 contributions, 10 original research papers, and 4 review papers. The review paper of Ko et al. [1] provides a comprehensive overview of the significant advancements in engineered organ-on-a-chip research in a general way while in the review presented by Kanabekova and colleagues [2], a thorough analysis of microphysiological platforms used for modeling liver diseases can be found. To get a summary of the numerical models of microfluidic organ-on-a-chip devices developed in recent years, the review presented by Carvalho et al. [5] can be read. On the other hand, Maia et al. [6] report a systematic review of the diagnosis methods developed for COVID-19, providing an overview of the advancements made since the start of the pandemic. In the following, a brief summary of the research papers published in this SI will be presented, with organs-on-a-chip, microfluidic devices for detection, and device optimization having been identified as the main topics.info:eu-repo/semantics/publishedVersio

Oncologic Thermoradiotherapy: Need for Evidence, Harmonisation, and Innovation

The road of acceptance of oncologic thermotherapy/hyperthermia as a synergistic modality in combination with standard oncologic therapies is still bumpy. This is partially due to the lack of level I evidence from international, multicentric, randomized clinical trials including large patient numbers and a long term follow-up. Therefore we need more level I EVIDENCE from clinical trials, we need HARMONISATION and global acceptance for existing technologies and a common language understood by all stakeholders and we need INNOVATION in the fields of biology, clinics and technology to move thermotherapy/hyperthermia forward. This is the main focus of this reprint. In this reprintyou find carefully selected and peer-reviewed contributions from Africa, America, Asia, and Europe. The published papers from leading scientists from all over the world covering a broad range of timely research topics might also help to strengthen thermotherapy on a global level

Proceedings of the Scientific-Practical Conference "Research and Development - 2016"

talent management; sensor arrays; automatic speech recognition; dry separation technology; oil production; oil waste; laser technolog

2015 IMSAloquium, Student Investigation Showcase

We want to express our gratitude for the generosity and steadfast support of all the experts and leaders who have nurtured These collaborative partnerships are the strength of our SIR program.https://digitalcommons.imsa.edu/archives_sir/1014/thumbnail.jp

06. 2015 IMSAloquium Student Investigation Showcase

https://digitalcommons.imsa.edu/class_of_2015/1004/thumbnail.jp